BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CFO Brian C. Stephenson sold 4,148 shares of the stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total transaction of $149,991.68. Following the transaction, the chief financial officer now directly owns 102,464 shares in the company, valued at $3,705,098.24. This trade represents a 3.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
BridgeBio Pharma Price Performance
Shares of NASDAQ BBIO traded up $0.04 during midday trading on Friday, reaching $36.85. The company's stock had a trading volume of 2,508,887 shares, compared to its average volume of 2,930,747. The stock has a market capitalization of $6.96 billion, a P/E ratio of -15.29 and a beta of 1.07. The firm has a 50 day moving average price of $31.71 and a 200-day moving average price of $27.85. BridgeBio Pharma, Inc. has a 12-month low of $21.62 and a 12-month high of $39.47.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. On average, equities analysts predict that BridgeBio Pharma, Inc. will post -2.56 EPS for the current year.
Hedge Funds Weigh In On BridgeBio Pharma
A number of hedge funds and other institutional investors have recently made changes to their positions in BBIO. Steward Partners Investment Advisory LLC raised its position in BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after acquiring an additional 472 shares during the period. Itau Unibanco Holding S.A. bought a new position in shares of BridgeBio Pharma during the 4th quarter valued at approximately $41,000. Sterling Capital Management LLC increased its stake in shares of BridgeBio Pharma by 554.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after purchasing an additional 1,514 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of BridgeBio Pharma in the 3rd quarter worth approximately $57,000. Finally, CWM LLC lifted its stake in BridgeBio Pharma by 132.9% in the third quarter. CWM LLC now owns 3,442 shares of the company's stock valued at $88,000 after purchasing an additional 1,964 shares during the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the company. Bank of America boosted their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, November 25th. Scotiabank boosted their price target on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Friday. Evercore ISI upped their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a report on Monday, December 23rd. HC Wainwright reiterated a "buy" rating and set a $49.00 price objective on shares of BridgeBio Pharma in a report on Thursday, February 13th. Finally, Citigroup boosted their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a report on Friday. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $51.67.
Check Out Our Latest Research Report on BBIO
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Featured Articles
Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
